Raphael Pharmaceutical Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-1.3M | $-1.5M | $-1.3M | $-3.4M | $-1.6M | $-718.0K |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $245.0K | $350.0K | $200.0K | $2.3M | — | — |
| Net Cash from Operating Activities | $-210.0K | $-532.0K | $-1.2M | $-759.0K | $-1.4M | $-779.0K |
| Investing Activities | ||||||
| Capital Expenditures | — | — | — | $2.0K | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | $-2.0K | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $236.0K | $321.0K | $1.1M | $896.0K | $1.5M | $824.0K |
| Net Change in Cash | — | — | $-58.0K | $135.0K | $58.0K | $45.0K |
| Free Cash Flow | — | — | — | $-761.0K | — | — |